Please provide your email address to receive an email when new articles are posted on . Young children with type 1 diabetes had similar glycemic outcomes using fast-acting insulin aspart vs. standard ...

The rising global diabetes burden, particularly Type 1 and Type 2, is a key driver for the rapid acting insulin market. As per the International Diabetes Federation, more than 530 million adults lived ...

Scientists in Melbourne have designed a new type of oral capsule that could mean pain-free delivery of insulin and other protein drugs. Co-lead researcher Professor Charlotte Conn, a biophysical ...

The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its approval ...

And the market for insulin has changed fast. Since 2023, drug companies have cut costs voluntarily, spurred by government ...

Regular (R) insulin is a short-acting, injectable insulin used for the management of diabetes. It is typically taken before meals to prevent glucose from rising after a person eats. Regular insulin is ...